Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Cloperastine

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Cloperastine
Cloperastine structure (above); (S)-cloperastine 3D molecule (below)
Clinical data
Other namesHT-11
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Identifiers
  • 1-[2-[(4-Chlorophenyl)-phenyl-methoxy]ethyl]piperidine
CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.020.948Edit this at Wikidata
Chemical and physical data
FormulaC20H24ClNO
Molar mass329.87 g·mol−1
3D model (JSmol)
  • Clc1ccc(cc1)C(OCCN2CCCCC2)c3ccccc3
  • InChI=1S/C20H24ClNO/c21-19-11-9-18(10-12-19)20(17-7-3-1-4-8-17)23-16-15-22-13-5-2-6-14-22/h1,3-4,7-12,20H,2,5-6,13-16H2 checkY
  • Key:FLNXBVJLPJNOSI-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Cloperastine (INN) orcloperastin, in the forms ofcloperastine hydrochloride (JAN) (brand namesHustazol,Nitossil,Seki) andcloperastine fendizoate, is anantitussive andantihistamine that is marketed as acough suppressant inJapan,Hong Kong,Brazil and in someEuropean countries.[1][2][3] It was first introduced in 1972 in Japan, and then inItaly in 1981.[4]

Side effects

[edit]

Adverse effects may include sedation, drowsiness, heartburn, and thickening of bronchial secretions.[5]

Pharmacology

[edit]

The precisemechanism of action of cloperastine is not fully clear, but several differentbiological activities have been identified for the drug, of which include:ligand of theσ1 receptor (Ki = 20 nM) (likely anagonist),[6]GIRK channelblocker (described as "potent"),[7][8][9][10]antihistamine (Ki = 3.8 nM for theH1 receptor),[3][6] andanticholinergic.[3][11] It is thought that the latter two properties contribute toside effects, such assedation andsomnolence, while the former two may be involved in or responsible for the antitussive efficacy of cloperastine.[6][7]

Synthesis

[edit]
Synthesis:[12] Patents:[13][14] Isomers:[15] China:[16]

The halogenation of 4-Chlorobenzhydrol [119-56-2] (1) withphosphorus tribromide intetrachloromethane gives 1-(Bromophenylmethyl)-4-chlorobenzene [948-54-9] (2). Treatment with ethylenechlorohydrin (2-Chloroethanol) [107-07-3] (3) gives 1-(4-Chlorobenzhydryl)oxy-2-chloroethane [5321-46-0] (4). Reaction withpiperidine (5) completes the synthesis ofCloperastine (6).

See also

[edit]

References

[edit]
  1. ^Elks J (14 November 2014).The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 301–.ISBN 978-1-4757-2085-3.
  2. ^Swiss Pharmaceutial Society, ed. (January 2000).Index Nominum 2000: International Drug Directory. Taylor & Francis. pp. 261–.ISBN 978-3-88763-075-1.
  3. ^abcCatania MA, Cuzzocrea S (2011)."Pharmacological and clinical overview of cloperastine in treatment of cough".Therapeutics and Clinical Risk Management.7:83–92.doi:10.2147/TCRM.S16643.PMC 3061847.PMID 21445282.
  4. ^William Andrew Publishing (22 October 2013).Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 1103–.ISBN 978-0-8155-1856-3.
  5. ^Schlesser JL (1991).Drugs Available Abroad, 1st Edition. Derwent Publications Ltd. p. 29.ISBN 0-8103-7177-4.
  6. ^abcGregori-Puigjané E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, et al. (July 2012)."Identifying mechanism-of-action targets for drugs and probes".Proceedings of the National Academy of Sciences of the United States of America.109 (28):11178–83.Bibcode:2012PNAS..10911178G.doi:10.1073/pnas.1204524109.PMC 3396511.PMID 22711801.
  7. ^abChung KF, Widdicombe J (30 September 2008).Pharmacology and Therapeutics of Cough. Springer Science & Business Media. pp. 230–.ISBN 9783540798422.
  8. ^Soeda F, Fujieda Y, Kinoshita M, Shirasaki T, Takahama K (May 2016). "Centrally acting non-narcotic antitussives prevent hyperactivity in mice: Involvement of GIRK channels".Pharmacology, Biochemistry, and Behavior.144:26–32.doi:10.1016/j.pbb.2016.02.006.ISBN 978-3-540-79842-2.OCLC 612742272.PMID 26892760.S2CID 30118634.
  9. ^Yamamoto G, Soeda F, Shirasaki T, Takahama K (April 2011)."[Is the GIRK channel a possible target in the development of a novel therapeutic drug of urinary disturbance?]".Yakugaku Zasshi.131 (4):523–32.doi:10.1248/yakushi.131.523.PMID 21467791.
  10. ^Kawaura K, Honda S, Soeda F, Shirasaki T, Takahama K (May 2010)."[Novel antidepressant-like action of drugs possessing GIRK channel blocking action in rats]".Yakugaku Zasshi.130 (5):699–705.doi:10.1248/yakushi.130.699.PMID 20460867.
  11. ^Korolkovas A (16 August 1988).Essentials of Medicinal Chemistry. Wiley.ISBN 978-0-471-88356-2.
  12. ^Arnold H, Brock N, Kuhas E, Lorenz D (March 1954). "[Effect of antihistaminic substances. I. Chemical constitution and pharmacological effect of the basic benzhydrylethers]".Arzneimittel-Forschung.4 (3):189–194.PMID 13159698.
  13. ^Anon.,GB 1179945  (1970 to Yoshitomi Pharmaceutical).
  14. ^Anon.,GB 670622  (1952 to Parke Davis & Co).
  15. ^Laura Puricelli,EP 0894794  (1999 to AESCULAPIUS FARMACEUTICI S.r.l.).
  16. ^陶文潘, 潘文驰, 潘兴长, 罗泳萍, 樊希祥,CN 104327014A  (2015 to 重庆市恒安化工有限公司).
Expectorants
Mucolytics
Cough suppressants
Opium alkaloids,
opioids,
and derivatives
Other
H1
Agonists
Antagonists
H2
Agonists
Antagonists
H3
Agonists
Antagonists
H4
Agonists
Antagonists
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
KCaTooltip Calcium-activated potassium channel
Blockers
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
LGICsTooltip Ligand gated ion channels
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(andprodrugs)
σ1
σ2
Unsorted
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cloperastine&oldid=1285110734"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp